Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference
April 08 2024 - 7:00AM
Business Wire
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology
company discovering and developing allogeneic gamma delta T cell
therapies for autoimmune diseases and cancer, today announced that
Chen Schor, President and Chief Executive Officer will participate
in a panel at the Canaccord Genuity Horizons in Oncology Virtual
Conference being held April 15, 2024.
Details of the event are as follows:
Panel: “Off-the-Shelf CART – Let’s Talk Lupus and Oncology”
Date: Monday, April 15, 2024 Time: 3:00 p.m. ET
The Adicet Bio team will be available for one-on-one
meetings throughout the conference. Please contact your sales
representative at Canaccord Genuity to register for a meeting with
the company.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for autoimmune diseases and cancer. Adicet is advancing a pipeline
of “off-the-shelf” gamma delta T cells, engineered with chimeric
antigen receptors (CARs), to facilitate durable activity in
patients. For more information, please visit our website at
https://www.adicetbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240408693156/en/
Adicet Bio., Inc. Investor and Media Contacts
Anne Bowdidge abowdidge@adicetbio.com
Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200
janhavi.mohite@sternir.com
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Apr 2024 to May 2024
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From May 2023 to May 2024